Substituted 5,5′-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands:: Synthesis and pharmacological evaluation

被引:61
作者
Muccioli, GG
Martin, D
Scriba, GKE
Poppitz, W
Poupaert, JH
Wouters, J
Lambert, DM
机构
[1] Catholic Univ Louvain, Fac Med, Ecole Pharm, Unite Chim Pharmaceut & Radiopharm, B-1200 Brussels, Belgium
[2] Univ Jena, Dept Pharmaceut Chem, D-07743 Jena, Germany
[3] Univ Jena, Dept Inorgan & Analyt Chem, D-07743 Jena, Germany
[4] Fac Univ Notre Dame Paix, Fac Sci, Lab Chim Biol Struct, B-5000 Namur, Belgium
关键词
D O I
10.1021/jm049263k
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A set of 30 substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one (thiohydantoins) derivatives was synthesized, and their affinity for the human CB, cannabinoid receptor has been evaluated. These compounds are derived from the previously described cannabinoid ligands 5,5'-diphenylimidazolidine-2,4-dione (hydantoins). The replacement of the oxygen by a sulfur leads to an increase of the affinity while the function-i.e., inverse agonism-determined by [S-35]-GTP gamma S experiments remains unaffected. Finally, to evaluate the molecular parameters that could influence the affinity of the thiohydantoins, molecular electrostatic potential as well as lipophilicity calculations were undertaken on representative thiohydantoins and hydantoins derivatives. In conclusion, 5,5'-bis-(4-iodophenyl)-3-butyl-2-thioxoimidazolidin-4-one (31) and 3-allyl-5,5'-bis(4-bromophenyl)-2-thioxoimidazolidin-4-one (32) possess the highest affinity for the CB, cannabinoid receptor described to date for the hydantoin and thiohydantoins series when compared in a same bioassay.
引用
收藏
页码:2509 / 2517
页数:9
相关论文
共 42 条
[1]   Visualization of solvation structures in liquid mixtures [J].
Bergman, DL ;
Laaksonen, L ;
Laaksonen, A .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 1997, 15 (05) :301-+
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   CB1 cannabinoid receptor signalling in Parkinson's disease [J].
Brotchie, JM .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (01) :54-61
[4]   Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor [J].
Calandra, B ;
Portier, M ;
Kernéis, A ;
Delpech, M ;
Carillon, C ;
Le Fur, G ;
Ferrara, P ;
Shire, D .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 374 (03) :445-455
[5]   Bidirectional control of airway responsiveness by endogenous cannabinoids [J].
Calignano, A ;
Kátona, I ;
Désarnaud, F ;
Giuffrida, A ;
La Rana, G ;
Mackie, K ;
Freund, TF ;
Piomelli, D .
NATURE, 2000, 408 (6808) :96-101
[6]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[7]   SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats [J].
Cohen, C ;
Perrault, G ;
Voltz, C ;
Steinberg, R ;
Soubrié, P .
BEHAVIOURAL PHARMACOLOGY, 2002, 13 (5-6) :451-463
[8]   Appetite suppression and weight loss after the cannabinoid antagonist SR141716 [J].
Colombo, G ;
Agabio, R ;
Diaz, G ;
Lobina, C ;
Reali, R ;
Gessa, GL .
LIFE SCIENCES, 1998, 63 (08) :PL113-PL117
[9]   Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides [J].
Cravatt, BF ;
Giang, DK ;
Mayfield, SP ;
Boger, DL ;
Lerner, RA ;
Gilula, NB .
NATURE, 1996, 384 (6604) :83-87
[10]   ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR [J].
DEVANE, WA ;
HANUS, L ;
BREUER, A ;
PERTWEE, RG ;
STEVENSON, LA ;
GRIFFIN, G ;
GIBSON, D ;
MANDELBAUM, A ;
ETINGER, A ;
MECHOULAM, R .
SCIENCE, 1992, 258 (5090) :1946-1949